HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

travoprost (Travatan)

an ocular hypotensive agent comparable with bimatoprost; used to reduce Ocular Hypertension to prevent Glaucoma

Also Known As:

Travatan; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; AL-6221; AL6221; Alcon brand of travoprost; Travatan Z

Networked: 266 relevant articles (47 outcomes, 75 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Konstas, Anastasios G P: 10 articles (01/2015 - 03/2006)
2.	Bergamini, Michael V W: 10 articles (06/2008 - 08/2002)
3.	Stewart, William C: 8 articles (01/2010 - 03/2003)
4.	Landry, Theresa A: 7 articles (06/2008 - 07/2005)
5.	Holló, Gábor: 6 articles (09/2013 - 12/2005)
6.	Denis, Philippe: 6 articles (01/2012 - 01/2006)
7.	Kahook, Malik Y: 5 articles (06/2014 - 04/2008)
8.	Stewart, Jeanette A: 5 articles (01/2010 - 03/2003)
9.	Mallick, Sushanta: 5 articles (06/2008 - 07/2005)
10.	Sullivan, E Kenneth: 5 articles (01/2007 - 05/2002)

Related Diseases

1.	Open-Angle Glaucoma (Glaucoma, Open Angle) 10/01/2014 - "The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma." 10/01/2014 - "The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients. " 04/01/2009 - "This study suggests that when both drugs are dosed in the evening the TTFC provides improved intraocular pressure reduction, compared with travoprost, over the 24 h curve and for each individual time point in primary open-angle glaucoma patients." 12/01/2004 - "Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study." 10/01/2014 - "Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma."
2.	Ocular Hypertension (Glaucoma, Suspect) 02/01/2013 - "Alternate day use of travoprost 0.004% was as safe and effective as its daily use in lowering the IOP in patients with ocular hypertension." 02/01/2013 - "Fourteen patients with ocular hypertension in both eyes have been randomly assigned to receive travoprost 0.004% once a day in 1 eye and once every other day in the other eye. " 02/01/2013 - "To compare the daily versus the alternate day use of travoprost 0.004% in lowering the intraocular pressure (IOP) in patients with ocular hypertension. " 02/01/2013 - "A short-term randomized clinical trial of daily versus alternate day use of travoprost 0.004% in the treatment of ocular hypertension." 05/01/2003 - "Two prospective, controlled, multicenter, double-masked studies--one lasting 6 months (n=594) and the other, 12 months (n=787)--examined the intraocular pressure (IOP)-lowering efficacy of travoprost in 1381 black and nonblack patients with open-angle glaucoma or ocular hypertension. "
3.	Glaucoma 01/01/2010 - "The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma." 03/01/2012 - "To evaluate the changes in intraocular pressure (IOP) and pupil size in 12 Beagles with inherited glaucoma after instillations of 0.033, 0.0033, 0.001, 0.00033, and 0.0001% travoprost (Travatan®-Alcon Laboratories, Inc., Ft Worth, TX, USA) in multiple single-dose studies. " 02/01/2009 - "Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study." 01/01/2007 - "The results from this study support the concept that the majority of glaucoma patients, who are responding inadequately to other glaucoma therapies, could benefit from a change to travoprost monotherapy or from the addition of travoprost to their existing therapy." 03/01/2014 - "DUES is a common side effect of topical travoprost treatment in Japanese glaucoma patients."
4.	Low Tension Glaucoma 01/01/2012 - "BAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%-13.9% of patients with normal tension glaucoma." 01/01/2014 - "This study aimed to evaluate the effect of travoprost with sofZia® preservative system for lowering the intraocular pressure (IOP) of Japanese normal tension glaucoma (NTG) patients. " 08/01/2008 - "The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial." 01/01/2014 - "The diurnal and nocturnal effects of travoprost in normal-tension glaucoma." 01/01/2014 - "Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects."
5.	Hyperemia 09/01/2008 - "Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control." 01/01/2012 - "Results of the safety analysis were consistent with the results from the individual studies for travoprost ophthalmic solution 0.004%, with ocular hyperemia being the most common side effect. " 08/01/2015 - "Hyperemia was the most frequent treatment-related adverse event with both formulations (travoprost 0.003%, 11.8%; travoprost 0.004%, 14.5%). " 09/01/2008 - "Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001). " 01/01/2007 - "Adverse events due to hyperemia occurred in 6.4% and 9.0% of patients treated with travoprost 0.004% without BAC and travoprost 0.004% with BAC, respectively. "

Related Drugs and Biologics

1.	Timolol (Blocadren)
2.	latanoprost (Xalatan)
3.	bimatoprost (Lumigan)
4.	travoprost (Travatan)
5.	brinzolamide (Azopt)
6.	dorzolamide (Trusopt)
7.	Benzalkonium Compounds (Benzalkonium Chloride)
8.	brimonidine (Alphagan)
9.	tafluprost
10.	hydroxide ion

Related Therapies and Procedures

1.	Phacoemulsification
2.	Aftercare (After-Treatment)
3.	Lasers (Laser)
4.	Stents
5.	Topical Administration